Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific is attractive because it combines a broad, diversified MedTech portfolio with a steady cadence of new products and above-industry growth, helped by rapid acceleration in Electrophysiology from the Farapulse pulsed field ablation ramp and other tailwinds such as Watchman LAA and AGENT DCB. The company’s outlook is further supported by tuck-in M&A and underappreciated launch opportunities, including Farawave Ultra, ICE, and Seismiq coronary IVL, while its newer businesses now represent a more durable growth profile after reducing reliance on commoditized cardiac rhythm management and drug-eluting stents. Financially, it is expected to post $21.29 billion of revenue in 2026 and $22.03 billion in 2027, with EPS of $3.29 and $3.40, while shares trade below 15x forward P/E, leaving valuation room for upside.

Boston Scientific is facing a deteriorating fundamental outlook as the 8-day cybersecurity breach disrupted manufacturing, processing, and shipping across its global network, leading to an estimated ~9% of revenue-producing days being affected and forcing meaningful cuts to Q3-26 and FY26 expectations. Competitive pressures in LAAC and EP, plus softer Watchman demand and guidance implying only 5%-6.5% reported sales growth in 2026 versus prior expectations of 7%-8.5%, point to slower top-line momentum and limited EPS upside. Management also signaled only 0-25 bps of operating margin expansion for 2026, while uncertainty around recovery timing, higher shipping and remediation costs, and ongoing execution missteps undermine confidence in the company’s near-term earnings power.